Digital Health
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Will Advanced Technology Simulations Lead To More And Better Drugs? Start-Up Schrodinger Says It Can
Schrodinger LLC is a leading player in the emerging high-stakes field of computational chemical simulation software to boost the quality and productivity of drug discovery and lead generation. Its business model relies heavily on validating theoretical concepts of science and engineering in real-world settings through partnerships with a blue-chip list of pharma and biotech companies.
Digital Deals And Life Sciences: Avoiding Death By A Thousand Pilots
EY executive survey yields insights into how digital technology is helping drive biopharma deal strategy and aiding companies to meet competitive challenges.
Winners Are Beginning To Emerge In Digital Health – But Without Planning Medtechs Risk Missing The Boat
The leading medtechs are starting to develop models for providers that show how to implement successful digital strategies, a trend that is serving to put pressure on companies that are yet to make a commitment, says ZS Associates' Pete Masloski.
Data And The Digital Horizon: Perspective From The Agency C-suite
While digital health applications represent a major opportunity for biopharma, acting on the premise – and realizing its promise – depends on quantum-level shifts in organizational design and cultural resilience to disruptive change. In an In Vivo interview, Omnicom Health Group’s SVP for Data Solutions Christina Kim says industry progress toward a digitized future varies, but the necessity to act is clear.
Doubling Pharma Value With Data Science
A once-in-a-generation opportunity has opened to digitally redesign a core part of the biopharma business. Capturing the opportunity requires vision and leadership; it’s not about the technology.
GE Healthcare’s New Value Proposition: The Strategic Language Of Software
For an industry whose central structural dilemma is the slow pace of progress from bench to bedside, GE stands out as an exemplar of success – its performance on speed-to-market product launch has been studied extensively by big pharma strategists. GE Healthcare’s Tom McGuinness tells In Vivo how his division is doubling down on this record, using software and data analytics to help biopharma become more efficient in moving products to patients.
More on Digital Health from Scrip, Pink Sheet & Medtech Insight.
Roche Pushes Personalization With $2.4Bn Foundation Buy-Out
By picking up the rest of Foundation Medicine, which is now valued at $5.3bn, the Swiss giant is expanding its leadership in cancer diagnostics, genomics and molecular information for personal medicine.
Size Doesn't Matter: US FDA Refines Dig-Health Pre-Cert Model
After receiving feedback from industry and other stakeholders, FDA has revised its "working model" for its planned pre-certification program for health software. It now states that size of a company will not preclude them from participating in the program. The agency has also refined how it will conduct appraisals.
US FDA’s Patient Input Guidance Opens Door Wider To Social Media Data Collection
Following stakeholder criticism of an earlier discussion paper, draft guidance does not automatically foreclose use of social media data as the primary source of qualitative research; however, agency says entities submitting such data for regulatory review must ensure rigor in methodology and data integrity.
Roche Pushes Personalization With $2.4bn Foundation Buy-Out
By picking up the rest of Foundation Medicine, which is now valued at $5.3bn, the Swiss giant is expanding its leadership in cancer diagnostics, genomics and molecular information for personal medicine.
Medicaid Targeting Telemedicine To Address Opioid Crisis
CMS sent guidance to state Medicaid directors on how to leverage federal funding authorities for telehealth counseling and gain reimbursement for remote monitoring programs to aid beneficiaries struggling with opioid substance abuse.
Scrip Asks... What Is The Future Of Biotech?
Scrip asked industry leaders during the BIO 2018 meeting to envision future changes to the rapidly evolving world of biotechnology, predicting what the next five years will bring.
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.